Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01606306 · ClinicalTrials.gov registry record · Phase 3

Individualized Therapy For Asthma in Toddlers

A Phase 3 study, sponsored by Milton S. Hershey Medical Center.

Completed
Registry status
Phase 3
Development phase
300
Enrollment target

NCT01606306: Completed Phase 3 study, sponsored by Milton S. Hershey Medical Center.

NCT01606306 is a Phase 3 study that has completed, run by Milton S. Hershey Medical Center. The registered enrollment target is 300 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01606306, a Phase 3 study, has completed, sponsored by Milton S. Hershey Medical Center.

COMPLETED
Registry status
Phase 3
Development phase
300 participants
Enrollment target

Study Summary

The INFANT study will test whether, in preschool children 12-59 months of age with persistent asthma, the following Step 2 asthma therapies will provide similar degrees of asthma control: 1. Daily inhaled corticosteroid (ICS) treatment, 2. Daily leukotriene receptor antagonist (LTRA) treatment, and 3. As-needed ICS plus short-acting beta agonist (as-needed ICS/SABA) rescue treatment.

Primary Outcome

The primary outcome was differential response to the three therapies on the basis of fixed threshold criteria for the following asthma control measures, which encompassed domains of risk and impairment: the time from the start of the treatment period to an asthma exacerbation treated with systemic corticosteroids, and the annualized number of asthma control days (ACDs) from within that period. ACDs were defined as full calendar days without symptoms, rescue medication use, or unscheduled healthc

Interventions

  • DRUG Montelukast
  • DRUG daily fluticasone propionate
  • DRUG as-needed fluticasone propionate

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2013-02
Est. Completion 2015-04
Phase Phase 3
Milton S. Hershey Medical Center

396 total trials

What the finished NCT01606306 record still lists

NCT01606306 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower).

The record links to 0 conditions, and to 3 interventions - of which Montelukast is the first listed.

NCT01606306 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01606306 about?

NCT01606306 is a clinical study titled "Individualized Therapy For Asthma in Toddlers". The INFANT study will test whether, in preschool children 12-59 months of age with persistent asthma, the following Step 2 asthma therapies will provide similar degrees of asthma control: 1. Daily inhaled corticosteroid (ICS) treatment, 2. Daily leukotriene receptor antagonist (LTRA) treatment, and...

What is the current status of trial NCT01606306?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2013-02. Estimated completion is 2015-04.

What interventions are being tested in trial NCT01606306?

The interventions under investigation include: Montelukast (DRUG), daily fluticasone propionate (DRUG), as-needed fluticasone propionate (DRUG).

Who is sponsoring clinical trial NCT01606306?

This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01606306's enrollment target sits among peer trials

300 1122nd of 2000 higher than 840 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01606306, the US trial registry maintained by the National Library of Medicine. NCT01606306 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.